Skip to main navigation Skip to main content

Page translation not available

This page is not available in the language that has been selected and will appear in English.

Search

Contact us

07 3737 4500

PO Box 3787

South Brisbane QLD 4101

Dr Stephen Fanning

MBBS, MSc, FRACP, FRCPA

  • Clinical Haematologist

Biography

Dr Stephen Fanning completed his Bachelor of Medicine and Bachelor of Surgery at the University of Queensland in 1980. He became a fellow of the Royal Australian College of Physicians and the Royal College of Pathologists of Australia in 1992.

From 1991 to 1993 Dr Fanning undertook the Terry Fox Physician and Scientist Fellowship as awarded by the National Institute of Canada in Vancouver. During this time he also completed a Master of Science with the University of British Columbia.

After his return to Brisbane, Dr Fanning received a National Health and Medical Research Council (NHMRC) Post Graduate Fellowship at the Leukaemia Foundation of Queensland’s Research Laboratory. In the following years Dr Fanning worked as a visiting haematologist with Royal Brisbane and Women’s Hospital, Mater Adult Hospital and Sullivan and Nicolaides Partners. In 1997 Dr Fanning became the director of haematology and oncology for the Prince Charles Hospital in Brisbane.

In 1998 Dr Fanning commenced a position as director of Haematology and Oncology Clinics of Australia (HOCA, now Icon) and has continued with the group to the present day. Dr Fanning continues to treat patients at Icon Cancer Centre Wesley, Chermside and South Brisbane.

Dr Fanning has a special interest in the treatment of leukaemia, myelodysplasia, lymphoma and Hodgkin’s disease.

Research

Trials being conducted by this doctor

OLYMPIA-3 / R1979-ONC-2105

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with diffuse large B-cell lymphoma (DLBCL) that have not been treated before (called "previously untreated"). Patients with DLBCL that have come back after treatment (called "relapsed"), or have not responded to treatment (called "refractory"), can also participate in this study.This study will be made up of Part 1A, Part 1B, and Part 2.The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy in Part 2 of the study.The aim of Part 2 of the study is to see how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab (the comparator drug), and chemotherapy, the current standard of care treatment approved for DLBCL. Standard of care means the usual medication expected and used when receiving treatment for a condition.The study is looking at several other research questions, including:What side effects may happen from taking the study drug when combined with chemotherapyHow much study drug is in the blood at different timesWhether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)The impact from the study drug on quality of life and ability to complete routine daily activities

Locations Wesley

Diagnosis Lymphoma - B-cell Non Hodgkin's